Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2912 | Pipeline™ Flex Embolization Device with Shield Technology™ Wiki | 0.71 |
| drug513 | Bariatric surgery Wiki | 0.71 |
| drug4039 | Tomeka® Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005322 | Fetal Membranes, Premature Rupture NIH | 0.71 |
| D017542 | Aneurysm, Ruptured NIH | 0.71 |
| D002532 | Intracranial Aneurysm NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002617 | Dilatation HPO | 0.71 |
| HP:0001788 | Premature rupture of membranes HPO | 0.71 |
| HP:0004944 | Dilatation of the cerebral artery HPO | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011419 | Placental abruption HPO | 0.71 |
| HP:0003826 | Stillbirth HPO | 0.50 |
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
Description: Occlusion is measured by the Raymond Roy Scale. Significant stenosis is classified as >50%.
Measure: Incidence of complete angiographic occlusion without significant stenosis, and no rebleeding or retreatment of the target aneurysm Time: at 180-dayDescription: Disabling stroke is defined as any post-procedural ischemic or hemorrhagic event that results in poor functional outcome (i.e. mRS ≥ 3 points) assessed at 90 days post stroke event through 180 day follow-up.
Measure: Incidence of neurological death or disabling stroke post-procedure. Time: at 180-dayDescription: Scale for measuring general neurologic function: 0- No symptoms at all No significant disability despite symptoms; able to carry out all usual duties and activities Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Moderate disability; requiring some help, but able to walk without assistance Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Severe disability; bedridden, incontinent and requiring constant nursing care and attention Dead
Measure: Good clinical outcome (modified Rankin Scale (mRS) 0-2) Time: at 30-day, 180-day and 365-day post procedureStudy title Spanish Registry of Pregnant Women with COVID-19 Protocol number and version Number 55/20. Version V8. Sponsors This registry is a project promoted by Dr. Oscar Martínez Pérez of the Obstetrics and Gynaecology department of the Puerta de Hierro University Hospital. Principal investigator of the registry National coordinator: Dr. Óscar Martínez Pérez. Obstetrics and Gynaecology Department. Puerta de Hierro University Hospital. Majadahonda. Epidemiologist: Maria Luisa de la Cruz Conti Researchers for each site: 100 sites from 32 Spanish provinces are included (Appendix 1) Funding Neither the hospitals nor the participating investigators will receive any financial compensation for their collaboration. A bank account has been opened at the hospital's Biomedical Research Foundation to receive donations: COV20/00021 - SARS-COV-2 and the COVID-19 disease Call financed by the Carlos III Institute of Health and co-financed with ERDF funds. Abstract Rationale: Knowledge about the impact of the SARS-CoV-2 virus on pregnancy is still scarce and all current recommendations are based on less than 100 cases published in the literature. To identify moderate effects (such as vertical transmission, obstetric morbidity, foetal death, maternal or neonatal death) and to allow accurate risk estimates, larger sample sizes than those currently available are required. Methods: Prospective observational study of pregnant women in whom SARS-CoV-2 infection is suspected at any time during pregnancy with positive test results for SARS-CoV-2, in order to create a registry of baseline characteristics of the pregnant woman, aspects related to the course of pregnancy and delivery, and related to the new-born, with an observation period of up to 14 days after delivery. Subsequently, several phased studies will be conducted to help establish and monitor the set of measures to improve the care of pregnant women. Discussion: The national registry for COVID-19 in pregnancy described here is a tool for sharing and centralizing data related to exposures to SARS-CoV-2 during pregnancy in a structured way. It should speed up the process of prospectively obtaining a large unbiased data set and will collect information at national level.
Description: MATERNAL MORTALITY MORBIDITY
Measure: MATERNAL COMPLICATIONS Time: 1 yearDescription: VERTICAL TRANSMISION
Measure: NEONATAL INFECTION Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports